

High throughput lesion evaluation and quality control for incorporating quantitative imaging metrics into clinical practice

Anisha Keshavan PhD¹, Kelly Leyden MRes¹, Barbara Dappert MD¹, Michael Iv MD^{1,2}, Michael Becich MS¹, Michael Towbin BS¹, David Hughes BSN¹, Annalise Miner BS³, Revere Kinkel MD³, Jennifer Graves MD³

¹Octave Bioscience, Menlo Park, CA, United States of America, ²Stanford University, CA, United States of America, ³University of California, San Diego, CA, United States of America



K.L. and A.K. are employees of **Octave Bioscience**, Inc.

M.I.'s contribution to this study was as a paid consultant, and was not part of his Stanford University duties or responsibilities.

Dr. Kinkel is a scientific consult and/or educational speaker for Alexion, Bristol Myers Squibb, Biogen, Sanofi/Genzyme and Roche/Genentech

GOAL

MRI quantitative lesion metrics in the clinic

- MS lesion counts and volumes are poised to be **salient clinical biomarkers of disease progression**
- Why don't we have widespread adoption?



Lesion Volume Lesion Counts Whole Brain Atrophy Spinal cord area etc...



Roadblock to clinical use: Quality Control bottleneck

- Automated segmentation methods have error rate
 - Algorithmic variability
 - Image quality variability
 - Low expert agreement
- Visual quality control (QC) is required before a clinical decision can be made.
- Visual QC is fundamentally *time consuming*
 - Especially if segmentation errors need to be edited

OBJECTIVE

Time efficient QC and training

- Use an efficient web interface¹ to quickly:
 - a. Evaluate experts and non-experts to understand and resolve disagreements
 - b. QC the output of automated lesion segmentation methods.
- Evaluate feasibility
 - a. number of lesions QC'd
 - b. intra-rater reliability
 - c. inter-rater reliability
 - d. the types of lesions that are disagreed upon

APPROACH

Braindr: App to quickly rate lesions

- Potential lesions (PLs) screened via binary "swipe" on app (right=pass, left=fail)
- 2D Triplanar view with lesion area blinking red \rightarrow **quick decision** making
- Compatible with smartphones, tablets, and desktop
- Toggle between T2 FLAIR and T1 images
- Adjust brightness/contrast



METHOD

Generate high volume of potential lesions to rate

- 3D T1 and T2 FLAIR images from 32 subjects were registered, N4 bias field corrected, and z-scored.
- Thresholded subtraction images (Z_FLAIR-Z_T1) at varying levels.
- Generated a triplanar image of each resulting segmentation (called a potential lesion, PL), resulting in over **80,000** individual PL's needing QC, which simulates a **high-throughput scenario with a high error rate**.
- Measured variability between and within raters by calculating the Intraclass correlation coefficients (ICC).

>14K images rated; reliable consensus

- Feasibility: **14,973** PLs were labelled by 5 raters.
- Inter-rater reliability for an average rating ICC(2,k) = 0.92, and individual ICC(2,1) = 0.74.
- Disagreements occurred more frequently on PL's in the brainstem, cerebellum, hippocampus, and basal ganglia.

Rater	ICC(1,1)
Neuroradiologist (MI)	0.97
Beginner (MB)	0.90
Tech 1 (AK)	0.87
Tech 2 (KL)	0.85
Neurologist (BD)	0.84

Intrarater Reliabilities

DISCUSSION

Feasible for high volume patient load in clinic

- We simultaneously evaluated raters, and QC'd lesions from an automated method using a quick, scalable, web application. This enables us to
 - 1) improve expert agreement on lesion identification
 - 2) develop better quality education materials for experts and non-experts alike
 - 3) train new raters quickly
 - 4) ensure the quality of the measurements at scale.

NEXT STEPS

Machine learning to triage lesion segmentation QC

- In a high-throughput scenario, we need a triage system for segmentation QC
- With the training dataset we've generated here, we can:
 - **Predict** which image segmentations will need more editing by raters
 - **Prioritize** the rating of potential lesions based on classification uncertainty to train models more quickly (Active Learning)
 - **Decide** which potential lesions should go to which raters (e.g. lesions in regions that are difficult to assess should go to more experienced raters)

Questions? Contact us: <u>akeshavan@octavebio.com</u>, <u>kleyden@octavebio.com</u>, <u>michaeliv@octavebio.com</u>

> Visit additional posters with Octave Bioscience P0055 P0063 P0082 P0091 P0552 P0590

